Azathioprine may benefit pediatric atopic dermatitis

August 21, 2012
Azathioprine may benefit pediatric atopic dermatitis
For pediatric patients with refractory atopic dermatitis, oral azathioprine is associated with clinical improvement, and measurement of thiopurine methyltransferase activity seems useful for monitoring treatment, according to a study published online Aug. 13 in the Journal of the American Academy of Dermatology.

(HealthDay) -- For pediatric patients with refractory atopic dermatitis (AD), oral azathioprine is associated with clinical improvement, and measurement of thiopurine methyltransferase (TPMT) activity seems useful for monitoring treatment, according to a study published online Aug. 13 in the Journal of the American Academy of Dermatology.

To examine appropriate use and monitoring of azathioprine for children with AD, Maura Caufield, from the Georgetown University School of Medicine in Washington, D.C., and Wynnis L. Tom, M.D., from the University of California in San Diego, prospectively followed 12 children with severe, recalcitrant AD who were treated with oral azathioprine. At baseline, TPMT activity was measured, and, at times of stable improvement, inadequate response, or change in response, the measurement was repeated, together with measurement of 6-thioguanine nucleotide and 6-methylmercaptopurine.

The researchers found that, for all but one patient, therapy correlated with clinical improvement, with few adverse effects. During treatment, three patients exhibited significant changes in TPMT activity: two had a mild decrease and one demonstrated enzyme inducibility, with enzyme activity increasing from intermediate to normal range. There was an inverse correlation between these changes and to therapy, which was not seen for 6-thioguanine nucleotide or 6-methylmercaptopurine levels.

"Our results suggest that TPMT activity can alter in either direction during treatment," the authors write. "Repeated measurement might be warranted, particularly in cases of nonresponse to treatment, to optimize dosing or to consider alternate therapy."

Explore further: Genetic-screening trial could reduce drug side-effects

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Genetic-screening trial could reduce drug side-effects

June 24, 2011

(Medical Xpress) -- Patients with a range of common inflammatory diseases that also have genetic variations leading to low levels of a particular enzyme in their bodies are at greater risk of suffering side-effects from the ...

Recommended for you

Gut environment could reduce severity of malaria

February 8, 2016

Microorganisms in the gut could play a role in reducing the severity of malaria, according to a new study co-authored by researchers at the University of Tennessee, Knoxville, and the University of Louisville.

Easier diagnosis for fungal infection of the lungs

January 18, 2016

A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.